Recruit Holdings Stock And 2 Japan Shares Backed By Strong Cash Flow

Global inflation in several major economies is easing, which puts more attention on companies that can fund their own growth through strong cash flows and solid balance sheets. That is where high quality undervalued stocks come in. These businesses are already doing the hard work internally. This article highlights 3 standouts from the High Quality Undervalued Stocks screener that could merit a closer look now.

The 3 stocks below are just a starting sample from this theme, and the full screen surfaces 19 more companies with equally compelling stories that are not covered here. To identify potential opportunities that fit your own criteria, head straight into the High Quality Undervalued Stocks screener to filter and analyze the highest conviction plays.

Chugai Pharmaceutical (TSE:4519)

Chugai Pharmaceutical is a Japan based drug maker focused on cancer, autoimmune and rare disease treatments, built around a portfolio of biologic and antibody therapies developed in house and with Roche. The company currently reports all of its ¥1,342,808 million revenue from pharmaceuticals and has a market value of about ¥11.7 trillion, which places it firmly in the large cap bracket on the Tokyo market.

Chugai Pharmaceutical stands out for its focus on high value biologic drugs like Hemlibra and Actemra, strong profitability with a 35.1% net margin, and analyst expectations for double digit earnings growth, yet it is still flagged by Simply Wall St as trading below their intrinsic value estimate. The recent AI research partnership with Phylo and progress on new uses for Enspryng indicate a pipeline that could matter for future results. However, reliance on a handful of flagship drugs and on Roche keeps concentration risk firmly on the table. If you are looking for quality growth in healthcare with both clear strengths and real trade offs, this is a story worth examining more closely.

Chugai Pharmaceutical’s high margin portfolio and analyst expectations for double digit earnings growth raise a simple question: Is the market pricing in the full story or missing key risks and upside within the analyst forecasts for Chugai Pharmaceutical

Build your own high quality healthcare shortlist

Chugai Pharmaceutical and the other two stocks in this article all came from a single Simply Wall St screener, but your edge comes from tailoring the filters to your own approach. Use our flexible Screener to mix valuation, growth, quality, balance sheet and risk filters, or start with one of our curated Investing Ideas.

Recruit Holdings (TSE:6098)

Recruit Holdings runs a global portfolio of HR technology, staffing and lifestyle platforms that connect workers with jobs and consumers with services like beauty, travel, dining, housing and education. It has a market value of about ¥22.5 trillion, which places it among the larger listed companies in Japan.

Recruit Holdings catches the eye because it sits at the intersection of HR tech, data and staffing, with earnings momentum to match. Net margin is around 15%, return on equity is over 30%, and management has been using buybacks and dividends along with upgraded guidance for FY2026/27 to return capital. At the same time, weak labor demand in key markets and slower adoption of new platforms like Indeed PLUS show that growth is not risk free. For investors who want exposure to hiring platforms and staffing with both quality signals and real execution questions still on the table, this is a business that deserves a closer look.

Recruit Holdings has earnings power, capital returns and HR tech reach that many investors follow. Yet the real story sits in how those threads connect inside the analysis report for Recruit Holdings

Murata Manufacturing (TSE:6981)

Murata Manufacturing is a leading supplier of ceramic based passive electronic components that sit inside smartphones, cars, data centers and a wide range of industrial and consumer devices. It generates about ¥1.25t from Components and ¥664.8b from Devices and Modules, with only a small contribution from Other activities, which keeps the business tightly focused on core electronic parts. With a market value around ¥13.3t, Murata Manufacturing sits firmly in Japan’s large cap electronics group.

Murata Manufacturing is positioned at the crossroads of long term themes such as connectivity, automotive electronics and data center demand. The stock is flagged as trading well below Simply Wall St’s fair value estimate, yet carries a high P/E multiple and a history of earnings declines over the past five years, alongside recently stronger results and upgraded 2027 guidance. Share price volatility, a funding structure reliant on external borrowing and a relatively new board mean the quality story comes with real risk. For investors seeking exposure to electronic components at a discounted DCF value, this setup may warrant closer scrutiny.

Murata Manufacturing’s valuation gap compared with a high P/E and revived guidance hints at a story investors have not fully joined up yet. The real twist sits inside the analysis report for Murata Manufacturing

Seeking Fresh Alternatives Before They Fly

Fresh stock ideas often gain momentum quickly, and the best entry points can be caught only while they sit under the radar for now. Do not delay, get in early.

• Spot companies building real traction before they hit every headline by scanning the 65 high quality undiscovered gems curated for strong fundamentals and under followed potential.
• Ride growing demand for secure payments and blockchain infrastructure by tracking the 19 cryptocurrency and blockchain stocks that focus on real businesses behind the crypto story.
• Target companies with strong payouts and staying power using the 37 dividend fortresses curated for investors who want income that can keep working while others are still looking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com